Founded in 2004 and based in Frederick, Maryland, BioFactura, Inc. specializes in commercial physical and biological research and development. The company's core mission is to advance biopharmaceutical innovation, focusing on the development of biosimilars and biodefense therapeutics. BioFactura offers a range of products and services, including the development of biosimilar drugs like Ustekinumab and biodefense solutions such as smallpox therapeutics. Their market focus spans both the healthcare sector and national defense.
Notable figures affiliated with BioFactura include Jeffrey N. Hausfeld and Rodeina Challand. The company has achieved significant milestones, such as securing a multi-million dollar contract for its smallpox biodefense therapeutic and publishing phase data on its Ustekinumab biosimilar. These accomplishments underscore BioFactura's impact on both public health and biodefense, positioning it as a key player in the biopharmaceutical industry.
